S100A16 drives hepatocellular carcinoma by promoting KCNJ8-mediated choline metabolic dysregulation and immunosuppression
Authors:
- Wenqing DaiWDWenqing Dai
- Haobin ZhaoHZHaobin Zhao
- Ying LiuYLYing Liu
- Mingshuai LiMLMingshuai Li
- Junjian XueJXJunjian Xue
- Xiaoyin WangXWXiaoyin Wang
- Baosu HuangBHBaosu Huang
- Shushan YanSYShushan Yan
- Donghua XuDXDonghua Xu
Open Access
- 18 November 2026
- journal article
- Published by Springer Nature in Cell Death & Disease
Abstract
Dysregulated choline metabolism is an established metabolic hallmark that fuels hepatic inflammation and tumorigenesis. However, the upstream regulators of this pathway in hepatocellular carcinoma (HCC) are incompletely understood. Here, we identify S100 calcium-binding protein A16 (S100A16) as a pivotal driver of HCC that operates through choline metabolic reprogramming. Integrated transcriptomic and metabolomic analyses revealed a strong association between S100A16 upregulation and choline metabolism dysregulation in HCC. Clinically, S100A16 was significantly elevated in HCC tissues and patient sera, and its high expression correlated with poor overall and disease-free survival. Functionally, S100A16 overexpression promoted, while its knockdown suppressed HCC cell proliferation, invasion, migration, endoplasmic reticulum (ER) stress, and the production of metabolite phosphatidylcholine in vitro. Consistent with this, S100A16 overexpression potentiated tumor growth in subcutaneous xenograft models and enhanced pulmonary metastasis in vivo. Mechanistically, we delineated a novel signaling axis wherein S100A16 activates the Wnt5A/B-β-catenin pathway, leading to the upregulation of potassium inwardly-rectifying channel subfamily J member 8 (KCNJ8), which in turn drives choline metabolism dysregulation and ER stress. Importantly, hepatocyte-specific conditional knockout of S100A16 in a murine HCC model not only attenuated these oncogenic processes but also remodeled the immunosuppressive tumor microenvironment by rescuing CD8 + T cell exhaustion and reducing the infiltration of CD206 + M2-type tumor-associated macrophages. In summary, our study unveils S100A16 as a central regulator of choline metabolism and immunosuppression in HCC, positioning it as a promising diagnostic biomarker and therapeutic target for this cancer.Funding Information
- Leading Team of Scientific and Technological Innovation, Shandong Provincial Health Commission
- Weifang Municipal Health Commission Research Project
- Natural Science Foundation of Shandong Province (ZR2024QC231)
- Natural Science Foundation of Shandong Province (ZR2025MS1348)